Engineered E. Coli Expression Control for High-Titer Spidroins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Recombinant production of spider silk proteins and elastin-like peptides is hindered by low titers and high production costs due to issues like plasmid instability, inclusion body formation, low solubility, and transcriptional errors, limiting their practical application and commercial scalability.
Innovation Solution
A modified E. coli strain with specific genetic mutations and a pLysS plasmid is used to inhibit basal expression of exogenous nucleotide sequences, allowing for high-titer production of disordered polypeptides such as spidroins and ELPs by controlling expression with a strong promoter that is deactivated in the absence of inducing agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If strong promoters are used to drive high-level expression of exogenous genes, then production titer is improved, but basal expression leads to metabolic burden and reduced cell viability
Solution Approach 1:
The patent applies preliminary action by pre-modifying the promoter sequence to reduce its basal activity before induction. The promoter is engineered in advance to have attenuated constitutive expression, so that when induction occurs, the system is primed for high-level expression without the metabolic burden of continuous basal expression. This resolves the contradiction by preparing the system beforehand to achieve high productivity only when needed, while maintaining cell viability during the uninduced state.
2Reliability
If induction is delayed to maintain cell viability, then cell health is improved, but production time increases
Solution Approach 1:
The patent applies parameter changes by modifying the promoter's expression kinetics parameters. The engineered promoter exhibits a sharper induction response with reduced lag time, allowing the system to transition rapidly from a low-expression state to a high-expression state. This resolves the contradiction by changing the temporal parameters of gene expression, enabling delayed induction without sacrificing productivity, as the induced expression phase is more intense and efficient.
3Productivity
If induction is extended to achieve high titers, then production yield is improved, but metabolic burden accumulates and reduces cell viability
Solution Approach 1:
The patent applies periodic action through controlled induction cycles. Instead of continuous induction, the system uses timed induction periods followed by recovery periods, allowing cells to express the exogenous gene at high levels during induction while recovering during non-induced periods. This resolves the contradiction by dividing the production process into periodic phases, accumulating high titers over multiple cycles while preventing metabolic burden from becoming overwhelming.
Data Source
AI summary
Recombinant E. coli strains and synthetic protein sequence designs are leveraged for production of disordered polypeptides such as spidroins and elastin-like peptides (ELPs). These disordered polypeptides, the high-titer production of which has proven difficult, include repeating structural motifs from a small selection of amino acid residues, resulting in lack of well-defined tertiary and quaternary structure. The recombinant E. coli include expression vectors with genes encoding for the disordered polypeptide product. Expression of these genes is controlled by a promoter that downregulates and substantially inhibits basal expression in the recombinant bacteria. Further, the recombinant bacteria include mutations to one or more stress-response genes from wild-type E. coli, such as yggw, yedv, yedw, yedy, spec, speb, uspc, hcha, loip, mltc, envz, ompr, yhgf, or hupb. The recombinant E. coli enable production of high titers of disordered protein product while minimizing the toxic effects thereof on the host.